21 research outputs found

    Particle Dark Matter Constraints from the Draco Dwarf Galaxy

    Get PDF
    It is widely thought that neutralinos, the lightest supersymmetric particles, could comprise most of the dark matter. If so, then dark halos will emit radio and gamma ray signals initiated by neutralino annihilation. A particularly promising place to look for these indicators is at the center of the local group dwarf spheroidal galaxy Draco, and recent measurements of the motion of its stars have revealed it to be an even better target for dark matter detection than previously thought. We compute limits on WIMP properties for various models of Draco's dark matter halo. We find that if the halo is nearly isothermal, as the new measurements indicate, then current gamma ray flux limits prohibit much of the neutralino parameter space. If Draco has a moderate magnetic field, then current radio limits can rule out more of it. These results are appreciably stronger than other current constraints, and so acquiring more detailed data on Draco's density profile becomes one of the most promising avenues for identifying dark matter.Comment: 13 pages, 6 figure

    Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers

    No full text
    Oncogenic mutations in RAS genes result in the elevation of cellular active RAS protein levels and increased signal propagation through downstream pathways that drive tumor cell proliferation and survival. These gain-of-function mutations drive over 30% of all human cancers, presenting promising therapeutic potential for RAS inhibitors. However, many have deemed RAS “undruggable” after nearly 40 years of failed drug discovery campaigns aimed at identifying a RAS inhibitor with clinical activity. Here we review RAS nucleotide cycling and the opportunities that RAS biochemistry presents for developing novel RAS inhibitory compounds. Additionally, compounds that have been identified to inhibit RAS by exploiting various aspects of RAS biology and biochemistry will be covered. Our current understanding of the biochemical properties of RAS, along with reports of direct-binding inhibitors, both provide insight on viable strategies for the discovery of novel clinical candidates with RAS inhibitory activity
    corecore